全文获取类型
收费全文 | 1089篇 |
免费 | 56篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 47篇 |
妇产科学 | 24篇 |
基础医学 | 57篇 |
口腔科学 | 47篇 |
临床医学 | 68篇 |
内科学 | 362篇 |
皮肤病学 | 35篇 |
神经病学 | 60篇 |
特种医学 | 38篇 |
外科学 | 242篇 |
综合类 | 7篇 |
预防医学 | 16篇 |
眼科学 | 59篇 |
药学 | 19篇 |
肿瘤学 | 47篇 |
出版年
2023年 | 4篇 |
2022年 | 10篇 |
2021年 | 18篇 |
2020年 | 7篇 |
2019年 | 10篇 |
2018年 | 13篇 |
2017年 | 12篇 |
2016年 | 26篇 |
2015年 | 20篇 |
2014年 | 39篇 |
2013年 | 46篇 |
2012年 | 74篇 |
2011年 | 68篇 |
2010年 | 43篇 |
2009年 | 42篇 |
2008年 | 89篇 |
2007年 | 124篇 |
2006年 | 83篇 |
2005年 | 77篇 |
2004年 | 69篇 |
2003年 | 48篇 |
2002年 | 49篇 |
2001年 | 36篇 |
2000年 | 23篇 |
1999年 | 25篇 |
1998年 | 5篇 |
1997年 | 4篇 |
1996年 | 9篇 |
1995年 | 3篇 |
1994年 | 4篇 |
1993年 | 2篇 |
1992年 | 8篇 |
1991年 | 6篇 |
1990年 | 5篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 10篇 |
1986年 | 6篇 |
1985年 | 2篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1981年 | 5篇 |
1980年 | 5篇 |
1979年 | 2篇 |
1977年 | 1篇 |
1975年 | 1篇 |
排序方式: 共有1150条查询结果,搜索用时 15 毫秒
11.
12.
13.
Yavuz Köksal Bilgehan Yalçin G. Burça Aydın Neriman Sarı Nalan Yazici Ali Varan 《Pediatric hematology and oncology》2013,30(8):619-624
This study evaluated the immuned response of the hepatitis A vaccine in children with cancer who were receiving chemotherapy. Twenty-eight patients with lymphomas or solid tumors and who had negative serology for hepatitis A were enrolled. The median age was 4.7 years (range 2–16). The patients received 1440 IU hepatitis A vaccine at 0 and 6 months. Seroconversion rates at the first and seventh months were 60% (n = 17/28 patients) and 89% (n = 24/27 patients). No adverse effects were observed. The hepatitis A vaccine was found to be effective and safe in children with cancer. 相似文献
14.
Ozan Yazici Mehmet Ali Nahit ?endur Sercan Aksoy 《World journal of gastroenterology : WJG》2014,20(22):6716-6724
The purpose of this review is to summarize the evidence of hepatitis C reactivation in cancer patients in the era of targeted therapies.Targeted therapies are novel therapeutics frequently used in cancer patients.During treatment with targeted therapies,viral replication is one of the major problems that can occur.The PubMed database,ASCO,and ASCO Gastrointestinal Cancer Symposium abstracts were searched up until September 15,2013 using the following search keywords:"targeted therapies,rituximab,alemtuzumab,brentuximab,hepatitis,hepatitis C reactivation,tyrosine kinase inhibitors,imatinib,mammalian target of rapamycin(mTOR)inhibitors,everolimus,anti-HER therapies,trastuzumab,pertuzumab,lapatinib,antiepidermal growth factor receptor therapies,cetuximab,panitumumab,and ipilimumab".Papers considered relevant for the aim of this review were selected by the authors.The data about rituximab-induced hepatic flare in hepatitis C virus(HCV)positive patients is controver-sial.However,there is the possibility of life-threatening hepatic flare that can develop after HCV ribonucleic acid(HCV-RNA)viral load increases.Routine followup of liver function tests should be advised.Especially in high-risk patients,such as those with baseline chronic active hepatitis and cirrhosis,and where there are plans to administer rituximab concomitantly with corticosteroids,it is advised to have close follow-up of HCV viral load.The data is insufficient to make accurate statements about the association of alemtuzumab therapy and HCV reactivation.However,alemtuzumab may cause deep immunosuppression.Due to this,it is better to follow up with liver function tests and HCV RNA levels during alemtuzumab therapy.Brentuximab has effects on antibody dependent cellular toxicity and may decrease humoral immunity.Thus,we believe that during brentuximab treatment of HCV infected patients,clinicians may encounter hepatitis C reactivation.There have been no reported cases of hepatitis C reactivation with imatinib therapy.However,there are many reports of hepatitis B reactivation with imatinib treatment.Based on the evidence of hepatitis B reactivation with imatinib and the effects of imatinib on immune system functions,we suggest that imatinib therapy might be a risk factor for HCV reactivation.Anti-human epidermal growth factor receptor 2 therapies are not associated with hepatic flare in HCV infected patients.Post-transplant studies reported that mTOR was safely administered to patients with active hepatitis C without causing hepatic flare.Cetuximab and panitumumab have not been associated with HCV reactivation.Two cases of HCV infected melanoma were safely treated with ipilimumab without any HCV reactivation or hepatic flare.Targeted therapies are a new and emerging area of oncology treatment modalities.While treating HCV infected cancer patients,clinicians should be mindful of the immunosuppressive properties of targeted therapies.Further randomized trials are needed to establish algorithms for this issue. 相似文献
15.
16.
17.
Akdemir R Ozhan H Yazici M Gunduz H Duran S Gurel C Ozdas S Uyan C Basar I Ulutin T 《Heart and vessels》2004,19(4):167-171
The angiotensin II receptor, losartan, has been found to inhibit platelet aggregability to some extent in in vitro experiments. There have been conflicting results about the in vivo effects of losartan. We sought to clarify the in vivo effect of losartan on platelet aggregation. Forty patients with grade I essential hypertension were treated with losartan for 3 weeks. Platelet aggregation tests with adenosine diphosphate (ADP) and ristocetin were analyzed and compared before and at the end of the study. Losartan effectively decreased systolic (SBP) and diastolic (DBP) blood pressure. Mean SBP before and after treatment was 159.6 ± 12.8 and 149.2 ± 17.3mmHg, respectively. Mean DBP decreased from 93.7 ± 8.2 to 87.7 ± 10.3mmHg after treatment. The results of the platelet aggregation tests with ADP and ristocetin were not significantly different when both rate and amplitude of maximal aggregation were included. Peak platelet aggregation with ADP regarding the lowest light transmission in the aggregometer was 59.8% ± 24.3% before and 58.3% ± 18.1% after the treatment. The same variables with ristocetin were 66.8% ± 21.6% and 60.8% ± 23.3%, respectively. In vivo effects of losartan on platelet aggregation with ADP and ristocetin were insignificant. 相似文献
18.
19.
Akdemir R Ozhan H Gunduz H Erbilen E Yazici M Duran S Orkunoglu F Albayrak S Imirzalioglu N Uyan C 《Acta cardiologica》2004,59(5):499-502
OBJECTIVES: The purpose of our study was to evaluate the significance of polymorphisms in HLA class II genes in coronary artery ectasia (CAE) patients. METHODS AND RESULTS: Twenty-six patients with CAE without associated cardiac defects were enrolled in the study. CAE was defined as luminal dilation of 1.5- to 2.0-fold of normal limits. Ninety-five healthy subjects who were donors for different organ transplantations, were chosen as control group. Physical examination, electrocardiography and chest X-ray were completely normal in these cases. Both the patients and the control group were screened and compared for their HLA class II genotypes. HLA-DR B1*13, DR16, DQ2 and DQ5 genotypes were significantly more frequent in the patient group.When the known risk factors of coronary heart disease were compared in the patients carrying these genotypes with the non-carrying group, no significant differences were encountered. CONCLUSIONS: HLA-DR B1*13, DR16, DQ2 and DQ5 may be associated with the pathogenesis and increase the risk of CAE. 相似文献
20.